Detailed price information for Krystal Biotech Inc (KRYS-Q) from The Globe and Mail including charting and trades.

Krystal Biotech (KRYS) stock gains as the company wins FDA RMAT designation for its lung cancer therapy KB707. Read more here ...

Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS) announced today that the United States Food and Drug Administration (FDA) granted Regenerative Medicine Advanced Therapy ...

RMAT designation requires preliminary clinical evidence addressing an unmet need in a serious disease and provides Fast Track ...

NCI-Led Study Shows Median PFS of 9.6 Months Results Presented at AACR Special Conference on Innovations in Prostate Cancer PRINCETON, N.J., Jan. 28, 2026 (GLOBE NEWSWIRE) -- PDS Biotechnology ...

Scientists at Mount Sinai have unveiled a bold new way to fight metastatic cancer by turning the tumor’s own defenses against ...

Dr. Stacy Lindborg is president and CEO of IMUNON, a clinical-stage company in phase 3 development with a lead DNA-mediated ...

OVATION 3 is IMUNON’s pivotal Phase 3 study of IMMN-001, an IL-12 gene-mediated immunotherapy, in women with advanced stage epithelial ovarian cancer. The study is supported with unprecedented overall ...

Scientists at the Icahn School of Medicine at Mount Sinai have developed an experimental immunotherapy that takes an unconventional approach to metastatic cancer: instead of going after cancer cells ...

naturopathic medicine, functional medicine, integrative medicine, thymosin alpha-1, immunosenescence, thymic involution, inflammaging, peptide therapy ...

Ovarian cancer standard of care has not advanced in over 30 years, but a new DNA-based immunotherapy could be a gamechanger, showing major survival gains in clinical trials.